CD47 (CD47 Molecule)

In addition, this study further prepared responsive liposomes for encapsulating the STING agonist cGAMP and modified them by covalent attachment to the HRB surface to form the composite material HRB@LC. This composite system can synergistically block CD47-SIRPα-mediated immune escape and activate the STING signal pathway, thereby enhancing systemic antitumor immune responses and significantly improving the efficacy of immunotherapy.

These data demonstrate that a combination of CD47 blockade and anti-PD1 therapy enhances tumor antigen presentation and immune cell infiltration, while further improving anti-tumor responses in combination with tumor-targeted radiotherapy. This study provides support for the rational design of combinatorial immunoradiotherapy, using anti-CD47 inhibitors and anti-PD1 therapy, in a clinical trial targeting locally advanced HPV-negative HNSCC.

In conclusion, this study systematically characterizes the clinical and immunological associations of CD47 across multiple cancers and highlights its potential role in pancreatic adenocarcinoma, supporting the further investigation of CD47 as a therapeutic target.

Structural modeling uncovered a three-way junction and 3' triple helix in lncRNA. Collectively, these data suggest that circulating inflammatory rewiring is associated with checkpoint-rich suppressor expansion and tumor immune quiescence, outlining integrated myeloid- and RNA-directed strategies for cancer research.

Collectively, these findings provide deeper insights into the molecular mechanism governing the interactions between CD47, its antibody, and SIRPα. This work establishes a foundation for the development of tumor immune checkpoint inhibitors targeting this pathway.

DSP216 with an 'active' (DSP216a), but not with an 'inactive' Fc (DSP216i), triggered CD16-signaling in a reporter cell line, and the combination of checkpoint blockade and ADCC by DSP216a potentiated NK-mediated cytotoxicity. These encouraging findings support the continued preclinical evaluation of DSP216.

The conjugate potently matured bone marrow-derived dendritic cells in vitro and, after simple intraperitoneal delivery, safely suppressed tumor growth in vivo. This myeloid-targeted CpG platform broadens the design space for TLR9 agonists and offers an off-the-shelf strategy for integrating innate and adaptive immunity against cancer.

P1, N=150, Recruiting, Nanjing Sanhome Pharmaceutical, Co., Ltd.

Importantly, combinatorial blockade of IGFBP2 and CD47 synergistically suppressed tumor growth and prolonged survival in orthotopic GBM models. Together, our findings uncovered the hypoxia-exosomal IGFBP2-CD47 axis in GBM immune evasion and provided a compelling rationale for combination therapy to improve immunotherapy efficacy in GBM.

PTT synergizes with CD47 blockade primarily by inducing CRT-dependent pro-phagocytic signaling to provide the "eat me" signal. In parallel, PTT downregulates ECM components, enabling the essential "come near me" process that facilitates macrophage infiltration into tumors. This dual approach significantly improves the macrophage based anti-tumor efficacy of CD47 blockade.

Finally, we verify that DNAJC13-knockout decrease tumor burden when treated with CD47 blockade. Overall, this study highlights a previously unrecognized regulator of CD47 and demonstrates the utility of high-throughput FACS-based CRISPR screening to uncover modulators of key immune checkpoint pathways.

Overall, we conclude that CBD downregulates CD47 expression and induces apoptosis involving VDAC-1 oligomerization. Furthermore, they also suggest that CBD's pro-apoptotic effects on primary human T cells should also be monitored if it is used as an anti-cancer adjuvant or neo-adjuvant therapeutic in cancer patients.